Search research articles
Contact Us
Filters
Showing results (141-150 of 166) with videos related to
Page
of 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
L A Renfro, A Grothey, D Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2002
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
E Van Cutsem, M Dicato, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1997
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer
R Labianca, S Cascinu, L Frontini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
Lancet (London, England)
|
April 28, 1999
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy
R Passalacqua, F Campione, C Caminiti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
British Journal of Cancer
|
January 14, 2012
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
C Boni, M Tiseo, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F Petrelli, E Rulli, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
S Cascinu, F Graziano, F Ferraù, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 166) with videos related to
Sort By:
Page
of 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
L A Renfro, A Grothey, D Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2002
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
E Van Cutsem, M Dicato, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1997
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer
R Labianca, S Cascinu, L Frontini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
Lancet (London, England)
|
April 28, 1999
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy
R Passalacqua, F Campione, C Caminiti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
British Journal of Cancer
|
January 14, 2012
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
C Boni, M Tiseo, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F Petrelli, E Rulli, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
S Cascinu, F Graziano, F Ferraù, et al.
Page
of 17